Autoimmune liver disease
Conditions
Interventions
Observation group:Na
Sponsors
West China Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Retrospective study: From January 2009 to April 2023, consecutive patients who fulfilled the following inclusion criteria were included: a) established diagnosis of PBC b) age > 18y, c) has not received any medication or other treatment in the past, and d) abdominal radiological examination within 90 days before UDCA treatment, f) had complete follow-up information at least 6 months after treatment. Propective study: This project aims to prospectively include patients who were diagnosed with ALD at West China Hospital of Sichuan University and underwent baseline multiparametric functional MRI examinations between August 2023 and December 2026. The inclusion criteria are as follows: Inclusion criteria: a) Age = 18 years old; b) Patients diagnosed with ALD by pathology; c) ECOG OS score from 0 to 1; d) Compliant with receiving standardized treatment; e) Within 7 days prior to enrollment, the following laboratory test results were obtained: AMA, antinuclear antibody (ANA), white blood cell (WBC), neutrophil granulocyte (NE), platelet (PLT), hemoglobin (Hb), ALB, TBIL, direct bilirubin (DBIL), indirect bilirubin (IBIL), ALT, AST, GGT Triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C); f) The patient voluntarily participates and signs an informed consent form; g) There are no contraindications for MRI examination
Exclusion criteria
Exclusion criteria: Retrospective study: Exclusion criteria: a) Insufficient evidence of confirmed ALD; b) Chronic liver disease with malignant tumors or other causes (such as viral hepatitis, alcoholic cirrhosis, non-alcoholic fatty liver, etc.); c) Merge with other immune system diseases (such as systemic lupus erythematosus, etc.); d) Previous history of immunosuppressive therapy or drug therapy; e) Follow-up time after treatment is less than 6 months; f) Patient lost to follow-up or missing important clinical data. Prospective study: Exclusion criteria: a) Insufficient evidence for ALD diagnosis; b) Chronic liver disease with malignant tumors or other causes (such as viral hepatitis, alcoholic cirrhosis, non-alcoholic fatty liver); c) Merge with other immune system diseases (such as systemic lupus erythematosus, IgG4 related diseases, etc.); d) Concomitant decompensated cirrhosis or severe liver failure; e) Previous history of immunosuppressive therapy or drug therapy; f) Any significant clinical and laboratory abnormalities that the researcher believes will affect the safety evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging parameters;Liver and kidney function; | — |
Secondary
| Measure | Time frame |
|---|---|
| PLT;PT;APTT; | — |
Countries
China
Contacts
Public ContactYun Zhang
West China Hospital
Outcome results
None listed